Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment Containing Enfuvirtide (Fuzeon) Associated With Two Active Molecules.

Trial Profile

Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment Containing Enfuvirtide (Fuzeon) Associated With Two Active Molecules.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2012

At a glance

  • Drugs Enfuvirtide (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms AMPHORE
  • Most Recent Events

    • 28 Nov 2011 Actual patient number is 4 as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Planned end date changed from 1 Dec 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top